# of Displayed Technologies: 10 / 50


Categories

DAT-CI knock-in mouse model carrying a modified dopamine transporter that maintains the transport function but resistant to cocaine inhibition and thus showing no rewarding cocaine effects
TS-058669 — A knock-in mouse model carrying a modified dopamine transporter that is resistant to cocaine inhibition and thus showing no rewarding cocaine effects.
Cocaine abuse has been an issue in the United States since the late 1980s. The highly addictive qualities along with the low cost ruined people’s lives and destroyed communities. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an overdose. Therefore, th…
  • College: College of Medicine (COM)
  • Inventors: Gu, Howard
  • Licensing Officer: Davis, Stewart

NET-CI knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that maintains the transport function and makes the transporter protein resistant to cocaine and antidepressants
TS-058668 — A knock-in mouse model with a modified norepinephrine transporter carrying triple mutations that makes the transporter protein resistant to cocaine and antidepressants.
Cocaine abuse has been an issue in the United States since the late 1980s. Furthermore, antidepressants also quite dangerous, with nearly 14% of users (who have bipolar disorder) experiencing dependence. Naloxone (marketed as Narcan) is highly effective but can only be used in the event of an over…
  • College: College of Medicine (COM)
  • Inventors: Gu, Howard
  • Licensing Officer: Davis, Stewart

Rabbit Model for Duchenne Muscular Dystrophy
TS-058084 — A rabbit model has been created for Duchenne Muscular Dystrophy (DMD) that more closely resembles the effects experienced in humans while being more cost effective compared to larger animal models.
There has yet to be a DMD animal model that bridges the gap between cost effectiveness and scientific relevance. This new rabbit model does that. DMD is a lethal genetic disease characterized by progressive muscle weakness and muscle wasting. There are several animal models for DMD, includin…
  • College: College of Medicine (COM)
  • Inventors: Han, Renzhi
  • Licensing Officer: Davis, Stewart

Anti-GARP Monoclonal Antibodies for Cancer Therapy
TS-057778 — A novel monoclonal antibody (PIIO-1) to be used in combination with immune-checkpoint blockers. PIIO-1 augments CD8+ T cells-induced anti-tumor immunity and overcomes ICB resistance by disrupting transforming growth factor-β (TGF-β), the center of a pathway significantly implicated in solid tumors and hematological malignancies. PIIO-1 inhibits TGFβ locally via a docking receptor, avoiding adverse and unforeseen side effects.
Although immune checkpoint blockade (ICB) has emerged as a promising cancer immunotherapy, a majority of tumors fail to respond to ICB. A potential mechanism driving this failed response is the accumulation of TGF-β1 in the tumor microenvironment (TME), which drives immune dysfunction by indu…
  • College: College of Medicine (COM)
  • Inventors: Li, Zihai
  • Licensing Officer: He, Panqing

An Orally Active, Selective Inhibitor of CD4+ T-Cell Activation That Blunts Left-Ventricular Remodeling and Improves Cardiac Function during Chronic Heart Failure
TS-057777 — A novel orally-active drug molecule that can inhibit pathological CD4+ T-cells at clinically translatable doses and, blunts progressive cardiac dysfunction and left-ventricular (LV) remodeling during Heart Failure (HF).
HF afflicts ~6.5 million adults in US with 50% mortality in first 5 years. It has an estimated market size of $4.2B USD in US alone with a forecasted CAGR of 23% from 2018-2028. Current HF treatments are mostly aimed at alleviating symptoms rather than treatment, resulting in progressive cardiac d…
  • College: College of Medicine (COM)
  • Inventors: Bansal, Shyam; Gumina, Richard
  • Licensing Officer: He, Panqing

Albumin-SN-38 Conjugate (AlbuCure) for Cancer Therapy
TS-057776 — A novel protein-drug conjugate of human serum albumin chemically conjugated to SN-38, solubilizing the potent chemotherapeutic. This therapy has the potential to treat many tumors with poor prognosis, including pancreatic, lung, breast, colorectal, ovarian, sarcoma, head and neck cancer, urothelial malignancies, and others.
Many solid tumors have poor prognosis despite recent progress in molecularly targeted therapy and immunotherapy. Irinotecan/CPT-11, a chemotherapy on the WHO Essential Medicines List, is approved for use in colorectal cancer, lung cancer, pancreatic cancer, gastric cancer, malignant glioma, and sa…
  • College: College of Medicine (COM)
  • Inventors: Williams, Terence; Lee, Robert
  • Licensing Officer: He, Panqing

Reduction in Incidence and Severity of Acute Graft-Versus-Host Disease (aGVHD) via CRISPR-Cas9 Deletion of the miR-155 Host Gene (MIR155HG) in Primary Human T Cells
TS-057739 — CRISPR/Cas 9 mediated targeting of MIR155HG in primary human T cells creates genomic deletions that disrupt transcription of mature microRNA-155 (miR-155, a miR associated with inflammation). Applying this treatment to donor T cells prior to allogenic hematopoietic stem cell transplantation (allo-HSCT) when treating hematological malignancies and other primary bone marrow disorders can prevent the development of aGVHD in patients.
The Need More than 8,000 patients receive allo-HSCT annually in the US alone as a cure for hematologic malignancies and other primary bone marrow disorders. However, the major barrier for the success of allo-HSCT is the high incidence of aGVHD and its associated morbidity and mortality. Acute GVHD…
  • College: College of Medicine (COM)
  • Inventors: Ranganathan, Parvathi; Garzon, Ramiro
  • Licensing Officer: He, Panqing

A novel mouse model of spontaneous chronic lymphocytic leukemia
TS-055268 — The laboratory of Dr. Rosa Lapalombella in collaboration with Dr. James Blachly at The Ohio State University has developed a mouse model of spontaneous Chronic Lymphocytic Leukemia.
The Need Chronic lymphocytic leukemia (CLL) accounts for one quarter of new cases of leukemia. CLL is the most prevalent adult leukemia in Western countries and is characterized by a mature B-cell phenotype. Given the burden of this disease, a large pipeline of drugs for treatment are in progress…
  • College: College of Medicine (COM)
  • Inventors: Lapalombella, Rosa; Blachly, James; Byrd, John
  • Licensing Officer: Davis, Stewart

Novel Ergonomic Scalpel Handle
TS-051663 — Alleviate and prevent occupational stresses using this novel scalpel design.
A highly unfortunate outcome of the 2020 coronavirus pandemic is the over 400,000 American deaths that have unexpectedly overloaded medical autopsy services across the United States. With this heightened need for autopsy services previously unseen occupational hazards relating to repetitive motion…
  • College: College of Medicine (COM)
  • Inventors: Sachire, Jennifer
  • Licensing Officer: Schworer, Adam

Novel acellular vaccine for protection against Bordetella infection
TS-050524 — Despite high vaccine coverage, whooping cough caused by Bordetella pertussis remains one of the most common vaccine-preventable diseases worldwide. Introduction of whole-cell pertussis (wP) vaccines in the 1940s and acellular pertussis (aP) vaccines in 1990s reduced mortality due to pertussis. Des…
  • College: College of Medicine (COM)
  • Inventors: Deora, Rajendar; Mishra, Meenu; Sukumar, Neelima
  • Licensing Officer: Schworer, Adam

Show More Technologies

Loading icon